World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?
about
New agents for the treatment of drug-resistant Mycobacterium tuberculosisEmerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanidRecent Developments and Future Opportunities in the Treatment of Tuberculosis in ChildrenMulti drug and other forms of drug resistant tuberculosis are uncommon among treatment naïve tuberculosis patients in TanzaniaA new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)Compounds for use in the treatment of mycobacterial infections: a patent evaluation (WO2014049107A1).Drug-resistant tuberculosis and advances in the treatment of childhood tuberculosis.Nanoparticle-Formulated Curcumin Prevents Posttherapeutic Disease Reactivation and Reinfection with Mycobacterium tuberculosis following Isoniazid Therapy.Surgical outcome of esophageal tuberculosis secondary to mediastinal lymphadenitis in adults: experience from single center in China.In silico-based high-throughput screen for discovery of novel combinations for tuberculosis treatmentIn vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis AntibioticsUsing Chemical Reaction Kinetics to Predict Optimal Antibiotic Treatment Strategies.Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis.In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium tuberculosis Isolates.Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy.Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice.Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies.Systematic review of clofazimine for the treatment of drug-resistant tuberculosis.The anti-tuberculosis agents under development and the challenges ahead.An Update on Repurposed Medications for the Treatment of Drug-Resistant Tuberculosis.Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline.The changing landscape in drug resistant-tuberculosis: an analysis of recent advances.2-aminoimidazoles potentiate ß-lactam antimicrobial activity against Mycobacterium tuberculosis by reducing ß-lactamase secretion and increasing cell envelope permeability.In vitro susceptibility of Mycobacterium tuberculosis isolates to an oral carbapenem alone or in combination with β-lactamase inhibitorsQuantitative analysis of clofazimine (Lamprene®), an antileprosy agent, in human dried blood spots using liquid chromatography-tandem mass spectrometry.The Physicochemical Basis of Clofazimine-Induced Skin Pigmentation.Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China.Outcomes of pulmonary MDR-TB: impacts of fluoroquinolone resistance and linezolid treatment.
P2860
Q26751463-21CC061E-CE68-4566-949A-982B8DE25277Q26771997-EE0031D7-F5C4-4B5E-9ABE-B6FA0E608B25Q27003210-4E01135C-9486-47DB-8496-45732CD3A5C5Q28085210-9FF36F5F-56B9-4048-A00A-B3A90BD704ABQ28545802-94FE1D16-03C5-4A34-9830-6701763666B3Q28602112-F8842CA3-2205-4096-B947-9C1FFEBBE4DAQ30907456-AB77F5E7-D04D-4DFA-951B-B81817FFE449Q33801345-B70B2D30-3D13-468A-8B0F-9F5BF3131D51Q33854476-6D2F36C7-7150-462B-BB53-DF48BB94EAE2Q34655735-1C678364-46E4-4428-B802-A8CAB6BAE90FQ35960910-517F5F83-EF5A-4AB6-8017-C3CF883A29E0Q36056408-6FB111B4-7749-44EA-8E2F-A2C80B94EA35Q36242447-4ED644FF-9FAD-430C-B600-5EB28CB86AEFQ36364155-3855856A-432A-443C-822C-285706142ACEQ36438910-0FCA3B33-B2BD-4AF6-9849-21D8E451595AQ36888058-BB1E952E-426D-484F-A58B-EF5EF0B29967Q37306561-F48B00B3-6A86-404B-A4E7-8E754B65A5C9Q37516784-7A3DA297-3300-470A-BF0F-3751C011182BQ38094353-07DABD4A-3CAE-4DBC-B76A-F42E89BD9DB9Q38617197-0E9E32DF-4D1C-4807-AD7F-333792777482Q38885365-A0A50DD9-7674-4139-A94C-D59CE1ACF572Q38995175-E4BBD976-3518-447C-80F6-BC338DE461A6Q39262652-9883E904-CAEA-4261-B6AE-9C89C134A0B6Q41293939-1D08AD0B-C11D-48A0-9839-968D3A14EECCQ42109610-02A251DB-F624-400A-A48A-DB9D840FF39DQ48193600-8C78FC90-AA5B-4D71-A56E-B7920914A5FAQ50085157-FF555BED-1BBF-4B5A-B365-F8F4A93E4605Q50453280-51A516C7-C057-48EC-A765-8109ECC145A8Q53205517-D76E2663-4DB2-4A53-9C3B-D6F96FA7C8F6
P2860
World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
World Health Organization grou ...... fficacy or untapped potential?
@en
type
label
World Health Organization grou ...... fficacy or untapped potential?
@en
prefLabel
World Health Organization grou ...... fficacy or untapped potential?
@en
P2093
P2860
P356
P1476
World Health Organization grou ...... fficacy or untapped potential?
@en
P2093
Carole Mitnick
Efficacy Subgroup, RESIST-TB
Ekwaro A Obuku
Eric L Nuermberger
Kelly E Dooley
Nadza Durakovic
Vera Belitsky
P2860
P304
P356
10.1093/INFDIS/JIS460
P407
P577
2012-07-17T00:00:00Z